Business Insider
My Markets Watchlist
Markets Stocks

SpringWorks Therapeutics Inc Registered Shs Stock , SWTX

46.79 -0.07 -0.15%
03:59:59 PM BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Wednesday 06/18/2025 the closing price of the SpringWorks Therapeutics Inc Registered Shs share was $46.79 on BTT. Compared to the opening price on Wednesday 06/18/2025 on BTT of $46.87, this is a drop of 0.17%. SpringWorks Therapeutics Inc Registered Shs's market capitalization is $2.88 B by 75.35 M shares outstanding.

SpringWorks Therapeutics Stock Snapshot

46.78
Bid
100.00
Bid Size
46.79
Ask
100.00
Ask Size
6/18/2025
Date
3:59 PM
Time
595,559.00
Volume
46.86
Prev. Close
46.87
Open
3.53 B
Market Cap in USD
75.35 M
Number of Shares
75.35 M
Total Number of Shares
46.74
Day Low
46.90
Day High
46.79
28.19
52 Week Low
61.42
52 Week High
46.79
0.00
Dividend in USD
0.00
Dividend Yield
96.81
Free Float in %
-3.48
EPS in USD
6.47
Book Value per Share in USD
-2.37
Cash Flow per Share in USD

Historical Prices for SpringWorks Therapeutics

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

SpringWorks Therapeutics Analyst Data

Total Analysts: 24
Buy Ratings: 20 Neutral Ratings: 4 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 47.00 Median: 62.88 Highest: 77.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

SpringWorks Therapeutics Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
05/12/25 Guggenheim
Maintained Hold $47
04/30/25 H.C. Wainwright & Co.
Downgraded to Hold $47
04/29/25 Guggenheim
Downgraded to Hold $47
04/28/25 Barclays Capital
Downgraded to Hold $47
02/24/25 H.C. Wainwright & Co.
Maintained Buy $74
02/21/25 H.C. Wainwright & Co.
Maintained Buy $74
02/12/25 Wedbush Morgan Securities Inc.
Maintained Buy $77
02/12/25 Evercore
Maintained Buy $65
02/12/25 H.C. Wainwright & Co.
Maintained Buy $74
06/04/24 H.C. Wainwright & Co.
Maintained Buy $74
05/31/24 H.C. Wainwright & Co.
Maintained Buy $74
05/06/24 H.C. Wainwright & Co.
Maintained Buy $74
03/06/24 H.C. Wainwright & Co.
Maintained Buy $74
03/06/24 J.P. Morgan
Maintained Buy $74
02/29/24 Barclays Capital
Maintained Buy $63
02/26/24 Wedbush Morgan Securities Inc.
Maintained Buy $70
01/25/24 Barclays Capital
Maintained Buy $47
11/29/23 Goldman Sachs
Maintained Buy $52
11/28/23 H.C. Wainwright & Co.
Maintained Buy $64
11/20/23 H.C. Wainwright & Co.
Maintained Buy $52
11/09/23 H.C. Wainwright & Co.
Maintained Buy $58
08/24/23 H.C. Wainwright & Co.
Maintained Buy $66
08/07/23 H.C. Wainwright & Co.
Maintained Buy $66
07/20/23 Goldman Sachs
Maintained Buy $49

SpringWorks Therapeutics Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 335 612 839 894 -
Dividend 0.00 0.00 - - -
Dividend Yield (in %) 0.00 % 0.00 % - - -
EPS -2.75 -0.83 1.72 3.90 -
P/E Ratio -17.05 -56.78 27.20 12.02 29.75
EBIT -231 -80 192 289 -
EBITDA -180 9 - - -
Net Profit -218 -66 203 318 -
Net Profit Adjusted -159 23 - - -
Pre-Tax Profit -218 -65 203 289 -
Pre-Tax Profit Reported -169 - - - -
EPS (Non-GAAP) ex. SOE -2.26 1.19 5.21 - -
EPS (GAAP) -2.75 -0.83 1.72 3.90 -
Gross Income 307 - - - -
Cash Flow from Investing 98 - - - -
Cash Flow from Operations -61 134 381 - -
Cash Flow from Financing - - - - -
Cash Flow per Share -0.27 1.83 - - -
Free Cash Flow -7 - - - -
Free Cash Flow per Share - - - - -
Book Value per Share 5.99 - - - -
Net Debt - - - - -
Research & Development Exp. 229 258 272 292 -
Capital Expenditure 2 - - - -
Selling, General & Admin. Exp. 336 408 388 223 -
Shareholder’s Equity 446 - - - -
Total Assets 548 - - - -
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts 7 7 6 8 6
Average Estimate -0.940 USD -0.797 USD -0.713 USD -2.750 USD -0.825 USD
Year Ago -1.185 USD -0.539 USD -0.721 USD -3.482 USD -
Publish Date - - - - -
Revenue Estimates
No. of Analysts 6 5 4 7 4
Average Estimate 59 USD 73 USD 87 USD 335 USD 612 USD
Year Ago 21 USD 60 USD 49 USD 192 USD -
Publish Date - - - - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 191.59 5.45 0.00 0.00 35.00 0.00 0.00
Change of sales in % 3,417.33 - - -100.00 - - -
Gross profit on sales 176.17 3.46 -1.90 -0.49 34.65 -0.19 -0.02
Gross profit on sales change in % 4,994.59 - -286.94 - - -1,008.03 -444.56
Operating income -278.13 -343.01 -280.67 -173.47 -46.32 -59.24 -18.49
Operating income change in % 18.92 -22.21 -61.80 -274.47 21.80 -220.37 -296.80
Income before tax -258.13 -325.10 -277.42 -173.91 -45.57 -58.31 -17.81
Income before tax change in % 20.60 -17.19 -59.52 -281.60 21.84 -227.32 -283.98
Income after tax -258.13 -325.10 -277.42 -173.91 -45.57 -58.31 -17.81
Income after tax change in % 20.60 -17.19 -59.52 -281.60 21.84 -227.32 -283.98

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 106.17 99.57 72.05 30.10 19.13 12.76 4.83
Long-term liabilities per share 0.08 0.29 0.34 0.00 0.03 0.02 0.03
Equity 481.10 626.22 558.19 422.40 557.06 322.07 43.56
Equity change in % -23.17 12.19 32.15 -24.17 72.96 - -360.94
Balance sheet total 587.28 725.79 630.24 452.49 576.19 334.83 48.39
Balance sheet total change in % -19.08 15.16 39.28 -21.47 72.08 591.94 357.29

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 2.58 0.09 0.00 0.00 0.81 0.00 0.00
P/E ratio (year end quote, basic EPS) - - - - - - -
P/E ratio (year end quote, diluted EPS) - - - - - - -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 -
Equity ratio in % 81.92 86.28 88.57 93.35 96.68 96.19 90.02
Debt ratio in % 18.08 13.72 11.43 6.65 3.32 3.81 9.98

SpringWorks Therapeutics Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
LYNCH DANIEL 05/13/2025 10,060.00 93,004.00 n/a Buy No
Lewis-Hall Freda C 05/13/2025 10,060.00 24,727.00 n/a Buy No
Fuhrman Alan 05/13/2025 10,060.00 24,727.00 n/a Buy No
Hambleton Julie 05/13/2025 10,060.00 14,155.00 n/a Buy No
ALBAN CARLOS 05/13/2025 10,060.00 28,861.00 n/a Buy No
Edris Badreddin 03/02/2025 400.00 169,712.00 56.20 Sell No
Edris Badreddin 03/02/2025 3,924.00 185,788.00 53.12 Sell No
Edris Badreddin 03/02/2025 12,078.00 173,710.00 54.26 Sell No
Edris Badreddin 03/02/2025 3,598.00 170,112.00 55.12 Sell No
Ashar Bhavesh 02/19/2025 1,016.00 62,053.00 61.19 Sell No
LYNCH DANIEL 02/19/2025 3,582.00 82,944.00 61.24 Sell No
LYNCH DANIEL 02/19/2025 44,018.00 86,526.00 60.14 Sell No
Islam Saqib 02/19/2025 5,068.00 1,034,625.00 61.24 Sell No
Islam Saqib 02/19/2025 24,260.00 1,039,693.00 60.10 Sell No
Islam Saqib 02/11/2025 13,186.00 1,074,625.00 59.28 Sell No
Islam Saqib 02/11/2025 85,309.00 1,087,811.00 n/a Buy No
LYNCH DANIEL 02/09/2025 69,766.00 236,178.00 53.23 Sell No
LYNCH DANIEL 02/09/2025 39,634.00 196,544.00 54.88 Sell No
Edris Badreddin 02/09/2025 30,000.00 189,712.00 53.13 Sell No
LYNCH DANIEL 02/09/2025 65,600.00 130,944.00 55.51 Sell No
Islam Saqib 02/09/2025 48,000.00 1,002,502.00 53.30 Sell No
Hambleton Julie 02/09/2025 13,774.00 4,095.00 53.01 Sell No
Pichl Daniel 02/09/2025 13,750.00 66,762.00 53.02 Sell No
Pichl Daniel 02/09/2025 7,000.00 50,762.00 57.15 Sell No
Pichl Daniel 02/09/2025 9,000.00 57,762.00 54.25 Sell No

SpringWorks Therapeutics Dividend Calendar

Date Name Dividend *yield Currency
2024 SpringWorks Therapeutics Inc Registered Shs 0.00 0.00 USD
2023 SpringWorks Therapeutics Inc Registered Shs 0.00 0.00 USD
2022 SpringWorks Therapeutics Inc Registered Shs 0.00 0.00 USD
2021 SpringWorks Therapeutics Inc Registered Shs 0.00 0.00 USD
2020 SpringWorks Therapeutics Inc Registered Shs 0.00 0.00 USD
2019 SpringWorks Therapeutics Inc Registered Shs 0.00 0.00 USD
2018 SpringWorks Therapeutics Inc Registered Shs - - USD
2017 SpringWorks Therapeutics Inc Registered Shs - - USD
*Yield of the Respective Date

SpringWorks Therapeutics Calendar

Event Estimate Info Date

SpringWorks Therapeutics Past Events

Event Actual EPS Info Date

SpringWorks Therapeutics Profile

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
OSZAR »